Antineoplastics

[ Brite menu | Download htext ]
    

1st Level  2nd Level  3rd Level  4th Level 

 Molecularly targeted agents
   Interleukin 2 receptor toxin
   Monoclonal antibody
   mTOR kinase inhibitor
   Proteosome inhibitor
   Receptor tyrosine kinase inhibitors
     Imatinib [ATC:L01XE01]
     Gefitinib [ATC:L01XE02]
     Erlotinib [ATC:L01XE03]
       D07907  Erlotinib (INN)
       D04023  Erlotinib hydrochloride (JAN/USAN)
     Sunitinib [ATC:L01XE04]
     Sorafenib [ATC:L01XE05]
     Dasatinib [ATC:L01XE06]
     Lapatinib [ATC:L01XE07]
     Nilotinib [ATC:L01XE08]
     Pazopanib [ATC:L01XE11]
     Vemurafenib [ATC:L01XE15]
     Crizotinib [ATC:L01XE16]
     Axitinib [ATC:L01XE17]
     Ruxolitinib [ATC:L01XE18]
   Retinoic acid receptor expression modification
 
 Hormones and hormone antagonist
 
 Biologic response modifiers
 
 Alkylating agents
 
 Antimetabolites
 
 Natural products
 
 Miscellaneous agents

[ DRUG | BRITE | KEGG2 | KEGG ]
Last updated: March 1, 2013

» Japanese version